Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01902472 · ClinicalTrials.gov registry record
A Prospective, Observational Study of Individuals Who Seroconvert While Taking Truvada® for Pre-Exposure Prophylaxis (PrEP)
A clinical trial, sponsored by Gilead Sciences.
- Completed
- Registry status
- 172
- Enrollment target
NCT01902472: Completed study, sponsored by Gilead Sciences.
NCT01902472 is a clinical trial that has completed, run by Gilead Sciences. The registered enrollment target is 172 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01902472 has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- 172 participants
- Enrollment target
Study Summary
This study will evaluate HIV-1 RNA and the presence or absence of resistance at baseline and following seroconversion, assess the frequency of HIV-1 screening and screening method(s) used for evaluation of seroconverters, and collect information regarding whether the seroconverter experienced signs and symptoms of acute HIV-1 infection prior to or at the time of seroconversion.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2013-09-02 |
| Est. Completion | 2017-10-30 |
What the finished NCT01902472 record still lists
NCT01902472 is an observational study that tracks outcomes without assigning an intervention. The registered 172 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01902472 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01902472 about?
NCT01902472 is a clinical study titled "A Prospective, Observational Study of Individuals Who Seroconvert While Taking Truvada® for Pre-Exposure Prophylaxis (PrEP)". This study will evaluate HIV-1 RNA and the presence or absence of resistance at baseline and following seroconversion, assess the frequency of HIV-1 screening and screening method(s) used for evaluation of seroconverters, and collect information regarding whether the seroconverter experienced signs ...
What is the current status of trial NCT01902472?
This trial is currently completed. The enrollment target is 172 participants. The study started on 2013-09-02. Estimated completion is 2017-10-30.
Who is sponsoring clinical trial NCT01902472?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04801797 · 172 participants · Phase 2
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
- NCT04867317 · 172 participants · Phase 3
Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)
- NCT05357040 · 172 participants · Phase 2
Antidepressant Effects of Nitrous Oxide
- NCT05587517 · 172 participants · Phase 2
A Clinical Trial of Interventions to Support Family Surrogates of Critically Ill Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI